MNPR · Monopar Therapeutics Inc.
AI read · Neutral
The AI's read
The report gives no new trial results, sales figures, or company forecast. It repeats an analyst's view, so it does not change how Monopar's business looks.
Morgan Stanley kept its Overweight rating on Monopar, a favorable opinion. But the update reports no new company results or changes, so it does not change Monopar's business outlook.
The report gives no new trial results, sales figures, or company forecast. It repeats an analyst's view, so it does not change how Monopar's business looks.
Follow Monopar Therapeutics Inc. (MNPR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MNPR